Addiction Updates Symposium | #ACMT2027
Includes a Live In-Person Event on 03/31/2027 at 1:30 PM (CDT)
-
Register
- Early bird pricing available!
- Non-member - Tier I - $200
- Non-member - Tier II - $137.50
- Non-member - Tier III - $87.50
- Non-member - Tier IV - $75
- Member - Tier I - $162.50
- Member - Tier II - $112.50
- Member - Tier III - $62.50
- Member - Tier IV - $50
- Regular Price after 02/18/2027 11:59 PM
- Non-member - Tier I - $275
- Non-member - Tier II - $212.50
- Non-member - Tier III - $162.50
- Non-member - Tier IV - $150
- Member - Tier I - $237.50
- Member - Tier II - $187.50
- Member - Tier III - $137.50
- Member - Tier IV - $125
2027 ACMT Addiction Symposium | Addiction Medicine: Updates, Controversies & Practical Pearls
March 31, 2027
Sheraton New Orleans Hotel, New Orleans, LA
Join the American College of Medical Toxicology (ACMT) on Thursday, March 31, 2027 for the 2027 ACMT Addiction Symposium | Addiction Medicine: Updates, Controversies & Practical Pearls at the Sheraton New Orleans Hotel in New Orleans, LA, for a half-day symposium highlighting current developments and practical approaches to the management of substance use disorders (SUD).
The symposium will feature Gail D’Onofrio, MD, MS, a nationally recognized expert in emergency medicine and addiction care at Yale School of Medicine, as a distinguished guest speaker.
The treatment of substance use disorder continues to evolve, with new approaches to medication induction, drug testing, and access to community-based care shaping clinical practice. Healthcare professionals must navigate changing guidelines, treatment options, and the complex needs of patients with co-occurring conditions.
This symposium will explore emerging strategies for addiction medicine, including alternative induction approaches using long-acting buprenorphine, updates to ASAM and ACMT drug testing guidelines, and changes in levels of care and access to community-based resources. Additional sessions will address low-dose ketamine to support withdrawal symptoms and treatment approaches for patients with co-occurring psychiatric and substance use disorders.
Featuring expert presentations and a panel discussion, this program is designed for healthcare professionals involved in the care of patients with SUD, including medical toxicologists, emergency medicine physicians, addiction medicine specialists, and other clinicians seeking practical updates for clinical practice.
Learner Objectives
After attending the event, participants should be able to:
- Identify gaps in training and clinical practice related to the diagnosis and ongoing management of substance use disorders.
- Discuss current guidelines, levels of care, and community-based resources for substance use disorder treatment.
- Apply evidence-informed strategies to support treatment, harm reduction, and continuity of care for patients with substance use disorders.

Continuing Education
Live and Enduring continuing education credits for Physicians and Pharmacists is provided by AKH Inc., Advancing Knowledge in Healthcare. It is expected that learners will receive up to 3.25 credits for learning and change.
You may also be interested in:
AACT Bayou Tox Symposium #ACMT2027 Main Conference
ACMT Chemical & Radiation Symposium ACMT Rural Tox Symposium
Questions?
Please write to ACMT at [email protected]
Agenda | March 31, 2027
All times listed are in local, Central Time.
1:15 - 1:30 PM CT
Welcome & Opening Remarks
1:30 - 2:15 PM CT
Alternative Induction Strategies
Gail D'Onofrio, MD, MS, Albert E. Kent Professor of Emergency Medicine, Professor of Epidemiology & Medicine Core Addiction, Yale School of Medicine
2:15 - 2:45 PM CT
Updates on Drug Testing Guidelines and SUD
Evan Schwarz, MD, FACEP, FACMT, FASAM, Clinical Professor of Emergency Medicine, Department of Emergency Medicine, University of California, Los Angeles
2:15 - 2:45 PM CT
Levels in Care: Updates in Accessing Community-Based Resources
Moderator
Ashley Haynes, MD, FACEP, Medical Toxicologist, Addiction Medicine Specialist, Veterans Health Administration
Leslie R. Dye, MD FACMT FASAM, Medical Director, OneFifteen, Clinical Professor, Department of Emergency Medicine, Boonshoft School of Medicine, Wright State University
3:30 - 3:45 PM CT | Break (15 min)
3:45 - 4:15 PM CT
Low Dose Ketamine to Support withdrawal Symptoms
R. Cole Pueringer, MD, Medical Toxicologist, Essentia Health
4:15 - 5:00 PM CT
Treating Dual-Diagnosis Panel
Moderator: R. Cole Pueringer, MD, Medical Toxicologist, Essentia Health
Timothy Wiegand, MD, DFACMT, DFASAM, Director & CEO, CMO Medicine and Toxicology & Addiction Consulting; President, ASAM
Matthew Dernbach, MD, Assistant Professor, Department of Psychiatry and Behavioral Medicine, Virginia Tech Carilion School of Medicine
5:00 - 5:15 PM CT
Closing Remarks
Continuing Education

Continuing Education credit for this activity is provided by AKH Inc., Advancing Knowledge in Healthcare. It is expected that learners will receive up to 3.25 for learning and change.
Available Continuing Educations Credits:
- Continuing Medical Education (CME)
- Continuing Pharmacist Education (CPE)

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and American College of Medical Toxicology (ACMT). AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME) and the Accreditation Council for Pharmacy Education (ACPE), to provide continuing education for the healthcare team. If you are seeking continuing education credit for a specialty not listed above, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.
Matthew Dernbach, MD
Assistant Professor, Department of Psychiatry and Behavioral Medicine
Virginia Tech Carilion School of Medicine
Dr. Matthew Dernbach is a board-certified psychiatrist, and an Assistant Professor of Psychiatry at the Virginia Tech Carilion School of Medicine. He earned his medical degree from the University of Rochester School of Medicine & Dentistry. He completed Psychiatry residency at the Medical University of South Carolina, Medical Toxicology fellowship at the Emory University School of Medicine/Centers for Disease Control and Prevention (CDC), and Addiction Psychiatry fellowship at Harvard University/Mass General Brigham. His work focuses on overdose continuum of care, substance use treatment, bioethics, and medical humanities.
Gail D'Onofrio, MD, MS
Albert E. Kent Professor of Emergency Medicine, Professor of Epidemiology (Chronic Diseases) and Professor of Medicine Core Addiction
Yale School of Medicine
Gail D’Onofrio, MD, MS is the Albert E. Kent Professor of Emergency Medicine and Professor of Medicine and Public Health at Yale University Schools of Medicine and Public Health. As a physician-scientist she has had continual NIH-funding for over two decades, designing and conducting clinical trials that have changed clinical practice. In addition, she was one of the founding members of the Board of Addiction Medicine, that became recognized as a ABMS approved subspecialty in 2016, sponsored by the American Board of Preventive Medicine. Dr. D’Onofrio is the MPI of the New England Consortium Node for the NIDA Clinical Trials Network and is the MPI of both a NIDA-funded and NINDS funded K12 training program.
Leslie R. Dye, MD, FACMT, FASAM
Medical Director, Next Life Recovery
Clinical Professor, Department of Emergency Medicine, Boonshoft School of Medicine, Wright State University
Leslie R. Dye, MD is triple board certified in emergency medicine, medical toxicology, and addiction medicine. She has worked in the fields of medical toxicology and addiction medicine for 30 years. In addition to her clinical expertise, she has academic and business content expertise from experiences as an editor-in-chief (EIC) of a peer-reviewed medical journal (Journal of Medical Toxicology) and EIC of physician and pharmacist content production for a leading international medical digital content provider. Her deep subject matter expertise is demonstrated in her role as senior editor of the textbook, Case Studies in Medical Toxicology, author of 18 peer reviewed publications and 16 textbook chapters, 66 national and 11 international presentations, 10 various commentaries, interviews, and podcasts. Her leadership skills have been proven in both corporate and academic environments, as professor at a medical school, long-term board member and past president of the American College of Medical Toxicology, Chair of the Addiction Medicine Committee, former co-chair, and co-moderator of the AACT Acute and Intensive Care Symposium, and as the manager of as many as 30 team members at an international corporation. She received a funded grant that enabled her to start the first poison control center in mainland China and trained 6 Chinese physicians in the field of medical toxicology over 3 years in the US. Dr. Dye is experienced in and continues to provide medical care in remote polar regions with no access to advanced medical facilities.
Ashley Haynes, MD, FACEP
Medical Toxicologist, Addiction Medicine Specialist
Veterans Health Administration
Dr. Haynes completed training in a combined emergency medicine-internal medicine program in 2014, and a toxicology fellowship at UTSW in 2016. She has been treating substance use disorders as part of her practice since that time and is board certified in addition medicine. She currently works for the VA at the Robert J Dole Veterans Medical Center in Wichita, KS, treating patients in a residential treatment center, as well as clinic, and performing bedside consults.
Robert "Cole" Pueringer, MD
Medical Toxicologist, Addiction Medicine Specialist, Hospitalist
Essentia Health in Duluth
Dr. Robert “Cole” Pueringer is a Medical Toxicologist, Addiction Medicine Specialist, and Hospitalist. He joined Essentia Health in September of 2022. He completed his medical training in the Twin Cities, including Medical School at the University of Minnesota, Internal Medicine Residency and Chief Resident year at Hennepin County Medical Center (HCMC). He received his CTropMed certification for Tropical Medicine & Travelers’ Health at the University of Minnesota. He then completed a Medical Toxicology fellowship at the Health Partners Institute/HCMC in 2021 and an Addiction Medicine fellowship at the University of Minnesota in 2022. His academic interests include medical education, Global Health, and the overlap of Medical Toxicology and Addiction Medicine. He is particularly passionate about substance use disorder - a disease that has affected many aspects of his own life – and hopes to contribute significantly to substance use treatment, education, de-stigmatization, and harm reduction in northern Minnesota.
Evan Schwarz, MD, FACMT
Clinical Professor of Emergency Medicine
University of California, Los Angeles
Dr. Evan Schwarz attended medical school at the University of Texas Medical Branch in Galveston, Texas, before completing a residency in Emergency Medicine at the Washington University School of Medicine in Saint Louis, Missouri. After residency, he completed a fellowship in Medical Toxicology at the University of Texas Southwestern School of Medicine in Dallas, Texas, before returning to Missouri where he was an Advisory Dean and the Medical Toxicology Division Chief and Fellowship Director at Washington University. In 2023, he took a position in the Department of Emergency Medicine at the University of California Los Angeles.
Timothy J. Wiegand, MD, FACMT, DFASAM
Director and CEO, Toxicology Consulting
Medicine, Addiction Toxicology Consulting PLLC, ASAM President Elect (2025-2027)
Dr. Tim Wiegand is the Director of Toxicology Consults and President of CMO Medicine and Toxicology & Addiction Consulting. Board-certified in both Medical Toxicology and Addiction Medicine, Dr. Wiegand specializes in Addiction Toxicology, combining clinical practice with research, teaching, and leadership roles. He has served two terms on the Board of Directors for the American College of Medical Toxicology (ACMT) and is currently on the Board of Directors for the American Society of Addiction Medicine (ASAM). From 2023-2025, he served as Treasurer of ASAM, having previously served as Vice President on the Executive Council. From 2025-2027, Dr. Wiegand will serve as ASAM President Elect and then ASAM President (2027-2029). Dr. Wiegand founded and led the Toxicology Service at URMC until 2022, when he transitioned to Director of Addiction Medicine and Director of Addiction Medicine Consults in the Department of Emergency Medicine. He also serves as Fellowship Director for the URMC Combined Addiction Medicine Fellowship and is leading efforts to launch the URMC Medical Toxicology Fellowship, which is expected to be formally accredited by July 2023.
Registration Rates
Registration includes:
- Access to the live in-person event on Wednesday, March 31, 2027
- Access to on-demand recording for 90 days after the event
- Access to the speaker slides
- Continuing Education credits available for Physicians and Pharmacists
| ACMT Member Rates | Early-Bird Expires: | Regular Rate Begins: Feb 19, 2027 |
|---|---|---|
Member Tier I: Full, Affiliate, International, Emeritus |
$162.50 | $237.50 |
Member Tier II: Fellows |
$112.50 | $187.50 |
Member Tier III: Residents, International - Developing Country |
$62.50 | $137.50 |
Member IV: Medical Students |
$50.00 | $125.00 |
| Non-Member Rates | Early-Bird Expires: | Regular Rate Begins: Feb 19, 2027 |
|---|---|---|
Non-member Tier I: Physicians, Pharmacists, Lawyers, "Other" |
$200.00 | $275.00 |
Non-member Tier II: Fellows, SPIs, Nurses, etc. |
$137.50 | $212.50 |
Non-member Tier III: Educators & Emergency Responders |
$87.50 | $162.50 |
Non-member IV: Residents & Students | $75.00 | $150.00 |
Early-Bird Rate
Early-bird rates expire at midnight on FEBRUARY 18, 2026. Fees increase to the Regular Rate after this date, no exceptions.
ACMT Membership
ACMT Members receive a discounted rate. Interested in becoming an ACMT Member? Contact our Membership Team at [email protected]. Learn more at: www.acmt.net/membership
Refunds and Cancellations
Event registration cancellations received on or before February 14, 2027 (2/14/27) will receive a full refund less a 8% processing fee. Cancellations received between February 14, 2027 and March 16, 2027 (2/14/27-3/16/27) will receive a 50% refund. Cancellations made on or after March 16, 2027 (3/16/27) will not receive a refund. All Continuing Education registrations will be refunded in full less an 8% processing fee regardless of date.
All cancellation requests must be made in writing and emailed to: [email protected]. No telephone cancellations will be accepted. A refund that results from a cancellation or change to your registration will be returned to the original payer and in the original method of payment.
Pending review, limited exceptions will be made based on need and circumstance and must be submitted in writing to [email protected]. Because each exception must undergo a review and approval process, we ask in advance for your patience.
Questions?
For any questions, please email us at [email protected].
Key:
Continuing Education

2027 ACMT Addiction Symposium | Addiction Medicine: Updates, Controversies & Practical Pearls Friday March 31, 2027
CE credit provided by AKH Inc., Advancing Knowledge in Healthcare.
Criteria for Success There is no fee to participate in this activity. Certificate of completion will be awarded based on the participant's attendance. A certificate of completion will be available upon completion of an online evaluation/claim credit form available at: https://education.acmt.net/p/2024TTC-SU-EP
Please claim your credit by June 29, 2027
If you have questions about this CE activity, please contact AKH Inc at [email protected]
In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and American College of Medical Toxicology (ACMT). AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 3.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and American College of Medical Toxicology (ACMT). AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 3.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

Physicians AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a maximum of 3.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician Associate
AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 3.25 AAPA Category 1 CME credits.
PAs should only claim credit commensurate with the extent of their participation.
Pharmacists AKH Inc., Advancing Knowledge in Healthcare designates this continuing education activity for 3.25 contact hour
Commercial Support This activity is supported from an independent medical education grant from BTG international lnc.,
Disclosures It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.
Disclosure of Unlabeled Use and Investigational Product This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participants misunderstanding of the content. If you would like to opt out from future communications from AKH please send an email to [email protected] with your information with "Opt Out" in the subject line.